Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.11
ALR's Cash to Debt is ranked lower than
55% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. ALR: 0.11 )
ALR' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.11

Equity to Asset 0.30
ALR's Equity to Asset is ranked higher than
51% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ALR: 0.30 )
ALR' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.77
Current: 0.3

-0.49
0.77
Interest Coverage 0.50
ALR's Interest Coverage is ranked lower than
60% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 116.56 vs. ALR: 0.50 )
ALR' s 10-Year Interest Coverage Range
Min: 0.04   Max: 3.6
Current: 0.5

0.04
3.6
F-Score: 5
Z-Score: 0.67
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 3.18
ALR's Operating margin (%) is ranked higher than
71% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. ALR: 3.18 )
ALR' s 10-Year Operating margin (%) Range
Min: -92.15   Max: 13.42
Current: 3.18

-92.15
13.42
Net-margin (%) -4.92
ALR's Net-margin (%) is ranked higher than
66% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. ALR: -4.92 )
ALR' s 10-Year Net-margin (%) Range
Min: -149.74   Max: 6.61
Current: -4.92

-149.74
6.61
ROE (%) -7.14
ALR's ROE (%) is ranked higher than
67% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. ALR: -7.14 )
ALR' s 10-Year ROE (%) Range
Min: -555.34   Max: 10.39
Current: -7.14

-555.34
10.39
ROA (%) -2.08
ALR's ROA (%) is ranked higher than
69% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. ALR: -2.08 )
ALR' s 10-Year ROA (%) Range
Min: -104.38   Max: 3.56
Current: -2.08

-104.38
3.56
ROC (Joel Greenblatt) (%) 9.24
ALR's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. ALR: 9.24 )
ALR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -445.57   Max: 66.78
Current: 9.24

-445.57
66.78
Revenue Growth (%) 13.30
ALR's Revenue Growth (%) is ranked higher than
89% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. ALR: 13.30 )
ALR' s 10-Year Revenue Growth (%) Range
Min: -8.6   Max: 73
Current: 13.3

-8.6
73
EPS Growth (%) -55.10
ALR's EPS Growth (%) is ranked lower than
51% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ALR: -55.10 )
ALR' s 10-Year EPS Growth (%) Range
Min: -55.1   Max: 75.3
Current: -55.1

-55.1
75.3
» ALR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ALR Guru Trades in Q3 2013

Paul Tudor Jones 21,100 sh (+142.53%)
Steven Cohen 26,489 sh (+75.42%)
Jim Simons 761,824 sh (+2.79%)
Diamond Hill Capital 801,161 sh (+2.06%)
Mario Gabelli 10,000 sh (unchged)
Pioneer Investments 74,600 sh (unchged)
Jeremy Grantham Sold Out
Chuck Royce 561,700 sh (-8.55%)
Manning & Napier Advisors, Inc 5,140,664 sh (-25.2%)
Private Capital 927,844 sh (-41.64%)
» More
Q4 2013

ALR Guru Trades in Q4 2013

Diamond Hill Capital 869,632 sh (+8.55%)
Mario Gabelli 10,600 sh (+6%)
Jim Simons 792,324 sh (+4%)
Private Capital 928,024 sh (+0.02%)
Pioneer Investments Sold Out
Chuck Royce 554,200 sh (-1.34%)
Manning & Napier Advisors, Inc 4,824,612 sh (-6.15%)
Steven Cohen 22,748 sh (-14.12%)
Paul Tudor Jones 8,700 sh (-58.77%)
» More
Q1 2014

ALR Guru Trades in Q1 2014

Pioneer Investments 272,081 sh (New)
Steven Cohen 242,783 sh (+967.27%)
Mario Gabelli 79,145 sh (+646.65%)
Diamond Hill Capital 986,820 sh (+13.48%)
Chuck Royce 615,700 sh (+11.1%)
Private Capital 935,449 sh (+0.8%)
Paul Tudor Jones Sold Out
Manning & Napier Advisors, Inc 4,809,827 sh (-0.31%)
Jim Simons 294,324 sh (-62.85%)
» More
Q2 2014

ALR Guru Trades in Q2 2014

Joel Greenblatt 11,057 sh (New)
John Keeley 1,335,700 sh (New)
Paul Tudor Jones 5,800 sh (New)
Mario Gabelli 242,845 sh (+206.84%)
Pioneer Investments 469,046 sh (+72.39%)
Chuck Royce 686,700 sh (+11.53%)
Diamond Hill Capital 1,066,212 sh (+8.05%)
Private Capital 920,989 sh (-1.55%)
Manning & Napier Advisors, Inc 4,431,073 sh (-7.87%)
Jim Simons 74,924 sh (-74.54%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2014-06-30 New Buy0.9%$32.86 - $37.68 $ 39.9712%1335700
Mario Gabelli 2014-06-30 Add 206.84%0.03%$32.86 - $37.68 $ 39.9712%242845
Joel Greenblatt 2014-06-30 New Buy0.01%$32.86 - $37.68 $ 39.9712%11057
Mario Gabelli 2014-03-31 Add 646.65%0.01%$33.99 - $39.34 $ 39.979%79145
Private Capital 2013-09-30 Reduce -41.64%1.54%$24.38 - $34.49 $ 39.9731%927844
Private Capital 2012-06-30 Add 35.93%0.71%$17.98 - $25.97 $ 39.9792%1734463
Seth Klarman 2012-06-30 Sold Out 0.12%$17.98 - $25.97 $ 39.9792%0
Mario Gabelli 2012-06-30 Reduce -25.93%$17.98 - $25.97 $ 39.9792%10000
Seth Klarman 2012-03-31 Reduce -93.12%1.3%$22.21 - $26.64 $ 39.9775%137700
Seth Klarman 2011-12-31 Reduce -35.48%0.72%$18.51 - $26.43 $ 39.9773%2000000
David Dreman 2011-12-31 Sold Out 0.53%$18.51 - $26.43 $ 39.9773%0
Mario Gabelli 2011-12-31 Reduce -27.03%$18.51 - $26.43 $ 39.9773%13500
Private Capital 2011-09-30 Add 13.49%0.27%$20.62 - $38.43 $ 39.9745%1353656
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB15.423.74

Guru Investment Theses on Alere Inc

Diamond Hill Capital Comments on Alere Inc - Oct 17, 2014

We initiated a new position in diagnostic systems provider Alere, Inc (ALR). We believe the company has the potential to grow intrinsic value by focusing on cost savings, asset disposals, and debt pay-down. All three of these initiatives would represent avenues to unmask the true long-term earnings power of the company and its core point-of-care diagnostics business. We forecast earnings well above the current consensus estimates.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Alere Inc

Diamond Hill Capital Comments on Alere Inc
We initiated a new position in diagnostic systems provider Alere, Inc (ALR). We believe the company has the potential to grow intrinsic value by focusing on cost savings, asset disposals, and debt pay-down. All three of these initiatives would represent avenues to unmask the true long-term earnings power of the company and its core point-of-care diagnostics business. We forecast earnings well above the current consensus estimates. Read more...
Private Capital Management Sells Update
The updated portfolio of Private Capital Management lists 71 stocks, three of them new, a total value at $1.09 billion, and a quarter-over-quarter turnover of 7%. The portfolio is currently weighted with top three sectors: technology at 26%, healthcare at 20.7%, and industrials at 14.8%. The stocks bought by Private Capital averaged a return of 9.91% over 12 months. Read more...

Ratios

vs
industry
vs
history
P/B 2.26
ALR's P/B is ranked higher than
82% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. ALR: 2.26 )
ALR' s 10-Year P/B Range
Min: 0.42   Max: 2.75
Current: 2.26

0.42
2.75
P/S 1.10
ALR's P/S is ranked higher than
90% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.96 vs. ALR: 1.10 )
ALR' s 10-Year P/S Range
Min: 0.52   Max: 4.12
Current: 1.1

0.52
4.12
PFCF 19.31
ALR's PFCF is ranked higher than
92% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALR: 19.31 )
ALR' s 10-Year PFCF Range
Min: 8.97   Max: 135.97
Current: 19.31

8.97
135.97
EV-to-EBIT 95.20
ALR's EV-to-EBIT is ranked higher than
72% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALR: 95.20 )
ALR' s 10-Year EV-to-EBIT Range
Min: -884.5   Max: 2833.4
Current: 95.2

-884.5
2833.4
Current Ratio 2.25
ALR's Current Ratio is ranked higher than
66% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ALR: 2.25 )
ALR' s 10-Year Current Ratio Range
Min: 0.7   Max: 3.42
Current: 2.25

0.7
3.42
Quick Ratio 1.70
ALR's Quick Ratio is ranked higher than
60% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. ALR: 1.70 )
ALR' s 10-Year Quick Ratio Range
Min: 0.46   Max: 2.89
Current: 1.7

0.46
2.89

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.98
ALR's Price/DCF (Projected) is ranked higher than
95% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ALR: 0.98 )
ALR' s 10-Year Price/DCF (Projected) Range
Min: 0.43   Max: 6.47
Current: 0.98

0.43
6.47
Price/Median PS Value 0.84
ALR's Price/Median PS Value is ranked higher than
89% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.26 vs. ALR: 0.84 )
ALR' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 3.12
Current: 0.84

0.39
3.12
Earnings Yield (Greenblatt) 1.10
ALR's Earnings Yield (Greenblatt) is ranked higher than
70% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. ALR: 1.10 )
ALR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 3
Current: 1.1

0.3
3
Forward Rate of Return (Yacktman) 3.69
ALR's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.68 vs. ALR: 3.69 )
ALR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2   Max: 9.4
Current: 3.69

-2
9.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:IM5.Germany
Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take charge of improving their health and quality of life at home by developing new capabilities in near-patient diagnosis, monitoring and health management. The Company's global products and services, as well as its new product development efforts, focuses on cardiology, infectious disease, toxicology, diabetes, oncology and women's health. The Company's main reportable operating segments are professional diagnostics, health management and consumer diagnostics. Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals and doctors' offices and, increasingly, testing and monitoring done at home at the direction of the medical professional, or through patient self-testing. Professional diagnostic products provide for qualitative or quantitative analysis of a patient's body fluids or tissue for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. The Company's health management business strives to empower participants of its programs and physicians so they could work together towards better health. It also provides services supporting home INR testing. Its health management business is principally conducted in the United States. The Company's other current consumer diagnostic products consist of its market-leading First Check brand of over-the-counter drugs of abuse tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for alcohol abuse, cholesterol monitoring and colon cancer screening. The Company's manufacturing facilities are located in San Diego, California; Scarborough, Maine; Dundee, Scotland; Oslo, Norway; Hangzhou and Shanghai, China; Matsudo, Japan; and Yongin, South Korea. It also manufactures products at a number of other facilities in the United States, Australia, Germany, India, Israel, South Africa, Spain and the United Kingdom. Its competitors in the United States and abroad are numerous and include, among others, diagnostic testing and medical products companies, universities and other research institutions, health management service providers, healthcare providers and health insurers. The main competitors for its professional rapid diagnostic products are Becton Dickinson, Quidel and Meridian Bioscience.
» More Articles for ALR

Headlines

Articles On GuruFocus.com
Diamond Hill Capital Comments on Alere Inc Oct 17 2014 
Diamond Hill Select Fund Third Quarter 2014 Commentary Oct 17 2014 
John Keeley Discloses Top New Stock Buys of Q2 Sep 17 2014 
Carl Icahn Bets on Hologic; Should You? Aug 19 2014 
Corsair Capital's Investment Thesis on Alere Inc. Jan 23 2014 
Private Capital Management Sells Update Nov 27 2013 
Performance - 11/15/2013 Nov 17 2013 
Microcap Man Chuck Royce Reveals Top New Stock Buys Feb 07 2013 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Are Regional Banks Free from European Exposure? Jan 27 2012 


More From Other Websites
Convening the Extraordinary General Meeting of Alior Bank S.A. Oct 31 2014
Decision of the Polish Financial Supervision Authority on inclusion of the proceeds from the issue... Oct 30 2014
Alere (ALR) Lags Q3 Earnings, Revenues; Outlook Positive Oct 29 2014
Dr. Mansoor Khan, CEO of Alere Analytics, to Share Vision on the Future of Big Data & Predictive... Oct 29 2014
[$$] Optum to Buy Alere Health Oct 28 2014
Optum, Alere Health to Combine to Help Health Plans, Employers and States Improve Population Health,... Oct 28 2014
Alere reports 3Q loss Oct 28 2014
Alere reports 3Q loss Oct 28 2014
Optum, Alere Health to Combine to Help Health Plans, Employers and States Improve Population Health,... Oct 28 2014
ALERE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 28 2014
Namal Nawana Named CEO and President of Alere Inc. Oct 28 2014
Alere Inc. Announces Third Quarter 2014 Results Oct 28 2014
Q3 2014 Alere Inc Earnings Release - Before Market Open Oct 28 2014
Fulfilling the last condition for the transition of the title to the shares in Polbita Sp. z o.o. Oct 24 2014
Altera Announces Third Quarter Results Oct 23 2014
Zmiany w skladzie Rady Nadzorczej Oct 22 2014
Alere Inc. Schedules Conference Call for 8:30 a.m. ET October 28, 2014 to Discuss Third Quarter 2014... Oct 21 2014
Execution of the agreement for the purchase of shares in Meritum Bank ICB S.A. Oct 20 2014
ALERE INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Oct 17 2014
Altera Announces Third Quarter Earnings Conference Call Oct 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK